Ocean Biomedical, Inc. financial data

Symbol
OCEA, OCEAW on Nasdaq
Location
515 Madison Ave Suite 8078, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Ocean Biomedical, Inc./DE (to 2/15/2023), Aesther Healthcare Acquisition Corp. (to 2/14/2023)
Latest financial report
Q3 2023 - Apr 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.5 % -96%
Debt-to-equity -103 % -121%
Return On Equity 162 %
Return On Assets -6.16 K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.6 M shares +2.59%
Common Stock, Shares, Outstanding 34.1 M shares
Weighted Average Number of Shares Outstanding, Basic 26.6 M shares +13.9%
Weighted Average Number of Shares Outstanding, Diluted 26.6 M shares +13.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 305 K USD -83.6%
General and Administrative Expense 2.35 M USD +78.7%
Operating Income (Loss) 1.83 M USD +16.3%
Nonoperating Income (Expense) -11.4 M USD -2209%
Net Income (Loss) Attributable to Parent -82.2 M USD -284%
Earnings Per Share, Basic -0.53 USD/shares -231%
Earnings Per Share, Diluted -0.53 USD/shares -231%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1.03 M USD +71.9%
Assets 1.03 M USD -99.1%
Accounts Payable, Current 16 M USD +8765%
Accrued Liabilities, Current 804 K USD -6.53%
Liabilities, Current 30.9 M USD +1375%
Liabilities 76.3 M USD +1355%
Retained Earnings (Accumulated Deficit) -179 M USD -7652%
Stockholders' Equity Attributable to Parent -75.2 M USD -665%
Liabilities and Equity 1.03 M USD -99.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.65 M USD -622%
Net Cash Provided by (Used in) Financing Activities 2.92 M USD +388%
Common Stock, Shares Authorized 300 M shares
Common Stock, Shares, Issued 34.1 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 272 K USD +17.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1 M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares +700%
Additional Paid in Capital 104 M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 186 K USD -93.7%
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%